BR0112456A - Compostos de piperidina para uso como inibidores de ccr-3 - Google Patents
Compostos de piperidina para uso como inibidores de ccr-3Info
- Publication number
- BR0112456A BR0112456A BR0112456-0A BR0112456A BR0112456A BR 0112456 A BR0112456 A BR 0112456A BR 0112456 A BR0112456 A BR 0112456A BR 0112456 A BR0112456 A BR 0112456A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- phenyl
- hydrogen
- compounds
- ccr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"COMPOSTOS DE PIPERIDINA PARA USO COMO INIBIDORES DE CCR-3". Compostos da fórmula na forma livre, onde Ar^ 1^ é fenila substituída por um ou mais átomos de halogênio, Ar^ 2^ é fenila ou naftila que está substituída ou não substituída por um ou mais substituintes selecionados de halogênio, ciano, hidróxi, nitro, C~ 1~-C~ 8~ alquila, C~ 1~-C~ 8~ haloalquila, C~ 1~-C~ 8~ alcóxi ou C~ 1~-C~ 8~ alcoxicarbonila, R^ 1^ é hidrogênio ou C~ 1~-C~ 8~ alquila opcionalmente substituída por hidróxi, C~ 1~-C~ 8~ alcóxi, acilóxi, -N(R^ 2^)R^ 3^, halogênio, carbóxi, C~ 1~-C~ 8~ alcoxicarbonila, -CON(R^ 4^)R^ 5^ ou por um grupo orgânico cíclico monovalente, R^ 2^ e R^ 3^ são cada um independentemente hidrogênio ou C~ 1~-C~ 8~ alquila, ou R^ 2^ é hidrogênio e R^ 3^ é acila ou -SO~ 2~R^ 6^, ou R^ 2^ ou R^ 3^ juntamente com o átomo de nitrogênio ao qual eles estão ligados significam um grupo heterocíclico de 5 ou 6 membros, R^ 4^ e R^ 5^ são cada um independentemente hidrogênio ou C~ 1~-C~ 8~ alquila, ou R^ 4^ e R^ 5^ juntamente com o átomo de nitrogênio ao qual eles estão ligados significam um grupo heterocíclico de 5 ou 6 membros, R^ 6^ é C~ 1~-C~ 8~ alquila, C~ 1~-C~ 8~ haloalquila ou fenila opcionalmente substituída por C~ 1~-C~ 8~ alquila, e n é 1, 2, 3 ou 4, com a condição de que quando Ar^ 1^ é p-clorofenila e R^ 1^ é hidrogênio, Ar^ 2^ não seja fenila ou p-nitrofenila. Os compostos são úteis como produtos farmacêuticos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0017174A GB0017174D0 (en) | 2000-07-12 | 2000-07-12 | Organic compounds |
GB0023326A GB0023326D0 (en) | 2000-09-22 | 2000-09-22 | Organic compounds |
PCT/EP2001/007941 WO2002004420A1 (en) | 2000-07-12 | 2001-07-10 | Piperidine coumpounds for use as ccr-3 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0112456A true BR0112456A (pt) | 2003-07-22 |
Family
ID=26244644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0112456-0A BR0112456A (pt) | 2000-07-12 | 2001-07-10 | Compostos de piperidina para uso como inibidores de ccr-3 |
Country Status (25)
Country | Link |
---|---|
US (1) | US6670379B2 (pt) |
EP (1) | EP1303488B1 (pt) |
JP (1) | JP2004502756A (pt) |
KR (1) | KR20030036603A (pt) |
CN (1) | CN1184204C (pt) |
AR (1) | AR031597A1 (pt) |
AT (1) | ATE447553T1 (pt) |
AU (2) | AU2001281972B2 (pt) |
BR (1) | BR0112456A (pt) |
CA (1) | CA2412941C (pt) |
CZ (1) | CZ200375A3 (pt) |
DE (1) | DE60140366D1 (pt) |
ES (1) | ES2334886T3 (pt) |
HU (1) | HUP0301341A2 (pt) |
IL (1) | IL153661A0 (pt) |
MX (1) | MXPA02012848A (pt) |
MY (1) | MY126139A (pt) |
NO (1) | NO324760B1 (pt) |
NZ (1) | NZ523414A (pt) |
PE (1) | PE20020616A1 (pt) |
PL (1) | PL358673A1 (pt) |
PT (1) | PT1303488E (pt) |
SK (1) | SK272003A3 (pt) |
TW (1) | TWI227231B (pt) |
WO (1) | WO2002004420A1 (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19952147A1 (de) * | 1999-10-29 | 2001-05-03 | Boehringer Ingelheim Pharma | Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
WO2002030898A1 (en) * | 2000-10-09 | 2002-04-18 | Novartis Ag | N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr33 receptor antagonists |
GB0114699D0 (en) * | 2001-06-15 | 2001-08-08 | Novartis Ag | Organic compounds |
PL1670482T5 (pl) * | 2003-09-16 | 2022-10-03 | Covis Pharma Gmbh | Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego |
US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
TW201524952A (zh) * | 2013-03-15 | 2015-07-01 | Araxes Pharma Llc | Kras g12c之共價抑制劑 |
TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Kras g12c之抑制劑 |
EP3280708B1 (en) | 2015-04-10 | 2021-09-01 | Araxes Pharma LLC | Substituted quinazoline compounds and methods of use thereof |
MX2017013275A (es) | 2015-04-15 | 2018-01-26 | Araxes Pharma Llc | Inhibidores triciclicos fusionados de kras y metodos de uso de los mismos. |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017058805A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
WO2017058768A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
CA3005089A1 (en) | 2015-11-16 | 2017-05-26 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
WO2018064510A1 (en) | 2016-09-29 | 2018-04-05 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
EP3573967A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused hetero-hetero bicyclic compounds and methods of use thereof |
US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
EP3573970A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
BR112019024674A2 (pt) | 2017-05-25 | 2020-06-16 | Araxes Pharma Llc | Inibidores covalentes da kras |
JP2020521741A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | がんの処置のための化合物およびその使用の方法 |
US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002510327A (ja) | 1997-07-25 | 2002-04-02 | メルク エンド カンパニー インコーポレーテッド | 環状アミンケモカイン受容体活性調節剤 |
US6339087B1 (en) | 1997-08-18 | 2002-01-15 | Syntex (U.S.A.) Llc | Cyclic amine derivatives-CCR-3 receptor antagonists |
IL125658A0 (en) * | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
BR9915403A (pt) | 1998-11-17 | 2001-08-14 | Hoffmann La Roche | Antagonistas receptores iii de 4-aroil-piperidin-ccr-3 |
AU3126700A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
TR200102800T2 (tr) * | 1999-03-26 | 2002-01-21 | Astrazeneca Ab | Yeni bileşikler. |
-
2001
- 2001-07-09 TW TW090116691A patent/TWI227231B/zh not_active IP Right Cessation
- 2001-07-10 IL IL15366101A patent/IL153661A0/xx unknown
- 2001-07-10 BR BR0112456-0A patent/BR0112456A/pt not_active IP Right Cessation
- 2001-07-10 ES ES01960488T patent/ES2334886T3/es not_active Expired - Lifetime
- 2001-07-10 EP EP01960488A patent/EP1303488B1/en not_active Expired - Lifetime
- 2001-07-10 PL PL01358673A patent/PL358673A1/xx not_active Application Discontinuation
- 2001-07-10 MY MYPI20013274A patent/MY126139A/en unknown
- 2001-07-10 PE PE2001000683A patent/PE20020616A1/es not_active Application Discontinuation
- 2001-07-10 US US10/332,642 patent/US6670379B2/en not_active Expired - Fee Related
- 2001-07-10 AT AT01960488T patent/ATE447553T1/de not_active IP Right Cessation
- 2001-07-10 JP JP2002509087A patent/JP2004502756A/ja active Pending
- 2001-07-10 NZ NZ523414A patent/NZ523414A/en unknown
- 2001-07-10 WO PCT/EP2001/007941 patent/WO2002004420A1/en active IP Right Grant
- 2001-07-10 KR KR10-2003-7000445A patent/KR20030036603A/ko not_active Application Discontinuation
- 2001-07-10 AU AU2001281972A patent/AU2001281972B2/en not_active Ceased
- 2001-07-10 SK SK27-2003A patent/SK272003A3/sk not_active Application Discontinuation
- 2001-07-10 DE DE60140366T patent/DE60140366D1/de not_active Expired - Lifetime
- 2001-07-10 AR ARP010103261A patent/AR031597A1/es unknown
- 2001-07-10 CZ CZ200375A patent/CZ200375A3/cs unknown
- 2001-07-10 PT PT01960488T patent/PT1303488E/pt unknown
- 2001-07-10 CN CNB018126111A patent/CN1184204C/zh not_active Expired - Fee Related
- 2001-07-10 AU AU8197201A patent/AU8197201A/xx active Pending
- 2001-07-10 HU HU0301341A patent/HUP0301341A2/hu unknown
- 2001-07-10 CA CA2412941A patent/CA2412941C/en not_active Expired - Fee Related
- 2001-07-10 MX MXPA02012848A patent/MXPA02012848A/es active IP Right Grant
-
2003
- 2003-01-10 NO NO20030135A patent/NO324760B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
DE60140366D1 (de) | 2009-12-17 |
NO20030135D0 (no) | 2003-01-10 |
ATE447553T1 (de) | 2009-11-15 |
NO20030135L (no) | 2003-02-19 |
ES2334886T3 (es) | 2010-03-17 |
CA2412941A1 (en) | 2002-01-17 |
PE20020616A1 (es) | 2002-08-02 |
EP1303488A1 (en) | 2003-04-23 |
AR031597A1 (es) | 2003-09-24 |
KR20030036603A (ko) | 2003-05-09 |
TWI227231B (en) | 2005-02-01 |
CA2412941C (en) | 2011-01-04 |
JP2004502756A (ja) | 2004-01-29 |
PL358673A1 (en) | 2004-08-09 |
MY126139A (en) | 2006-09-29 |
WO2002004420A1 (en) | 2002-01-17 |
NO324760B1 (no) | 2007-12-10 |
US20030176460A1 (en) | 2003-09-18 |
HUP0301341A2 (hu) | 2003-08-28 |
AU2001281972B2 (en) | 2004-06-03 |
CZ200375A3 (cs) | 2003-04-16 |
AU8197201A (en) | 2002-01-21 |
IL153661A0 (en) | 2003-07-06 |
NZ523414A (en) | 2004-07-30 |
EP1303488B1 (en) | 2009-11-04 |
CN1441780A (zh) | 2003-09-10 |
PT1303488E (pt) | 2010-01-19 |
CN1184204C (zh) | 2005-01-12 |
SK272003A3 (en) | 2003-07-01 |
US6670379B2 (en) | 2003-12-30 |
MXPA02012848A (es) | 2003-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0112456A (pt) | Compostos de piperidina para uso como inibidores de ccr-3 | |
BR0115478A (pt) | Aminotiazós e o uso dos mesmos como antagonistas do receptor da adenosina | |
CO5640117A2 (es) | Derivados de 2,4-diamonopirimidina | |
ES2188016T3 (es) | Derivaqdo de benzamidoxima, productos intermedios y procedimiento para su obtencion y su empleo como fungicidas. | |
CO6150144A2 (es) | Inhibidores de proteina tirosina fosfatasa humana y metodos de uso | |
DK1131315T3 (da) | Polyhydroxylerede heterocykliske derivater som antikoagulanter | |
EA200701176A1 (ru) | Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их | |
CR9690A (es) | 3-acilaminobenzanilidas insecticidas | |
BR0206433A (pt) | Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto | |
DK1337518T3 (da) | Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren | |
DE602004022404D1 (de) | 4-anilino-chinazolin-derivate als proliferationshemmende mittel | |
AR028531A1 (es) | Compuestos organicos | |
DOP2011000061A (es) | Compuestos de pirrol | |
ATE260275T1 (de) | Substituierte thien-3-yl- sulfonylamino(thio)carbonyl-triazolin(thi)one | |
BR0207278A (pt) | Derivados de ftalazinona-piperidina como inibidores de pde4 | |
BRPI0506927A (pt) | compostos orgánicos | |
EA200700758A1 (ru) | Новые производные бис-азаиндолов, их получение и фармацевтическое применение в качестве ингибиторов киназ | |
BRPI0413467A (pt) | aminopironas e seu uso como inibidoras da atm | |
CO5580821A2 (es) | 4-cetolactamas y -lactonas 3-fenil-3-substituidas, espirociclicas | |
ECSP034531A (es) | Derivados sustituidos de c-ciclohexilmetilamina | |
AR055666A1 (es) | Inhibidores inntr | |
CY1105786T1 (el) | Εκδοχα φλαβονων η διαδικασια παρασκευης τους, η εφαρμογη τους ως φαρμακα | |
BR112014010707A2 (pt) | compostos pesticidas | |
CR7249A (es) | Derivados de diamina, proceso para producir los derivados de diamina, y funguicidas que contienen los derivados de diamina como ingrediente activo | |
CO5680409A2 (es) | Derivados de benzazepina como inhibidores de mao-b |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012. |